ENHERTU Combination Secures EU Validation, Challenging First-Line Breast Cancer Standard
Event summary
- The European Medicines Agency (EMA) validated a Type II Variation application for ENHERTU (trastuzumab deruxtecan) in combination with pertuzumab for first-line treatment of HER2 positive metastatic breast cancer.
- The application is based on data from the DESTINY-Breast09 Phase 3 trial, presented at ASCO 2025 and published in The New England Journal of Medicine.
- DESTINY-Breast09 demonstrated a statistically significant improvement in progression-free survival (PFS) compared to the standard THP regimen.
- ENHERTU in combination with pertuzumab is already approved in the U.S. for this indication.
The big picture
The validation represents a significant challenge to the established THP standard of care, which has remained largely unchanged for over a decade. This approval, following the U.S. approval, positions ENHERTU as a leading ADC in oncology and underscores the growing importance of targeted therapies in treating aggressive cancers. The global breast cancer market is substantial, with over 2 million cases diagnosed annually, and this new treatment option has the potential to capture a significant share.
What we're watching
- Regulatory Scrutiny
- The EMA's review process will be critical; any unexpected requests for additional data could delay or alter the approval timeline, impacting Daiichi Sankyo and AstraZeneca’s revenue projections.
- Market Adoption
- The speed with which oncologists adopt the new combination therapy will depend on reimbursement decisions and physician familiarity, potentially impacting peak sales forecasts.
- Competitive Landscape
- The success of ENHERTU plus pertuzumab will likely spur increased R&D investment in other HER2-targeted therapies, intensifying competition within the metastatic breast cancer treatment space.
Related topics